TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05847491

Intervention type: DIAGNOSTIC_TEST
Intervention: IGRA/Tuberculin skin test
Description: All patients will receive:~* Clinical evaluation;~* Chest x-ray.~* IGRA (or tuberculin skin test if immunocompromised)~* Therapeutic proposal if eligible
Study: NCT06431243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A group Purinostat Mesylate 6mg/m2
Description: Purinostat Mesylate 6mg/m2 + EM 25mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A group Purinostat Mesylate 8.4mg/m2
Description: Purinostat Mesylate 8.4mg/m2 + EM 25mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A group Purinostat Mesylate 11.2mg/m2
Description: Purinostat Mesylate 11.2mg/m2 + EM 25mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A group Purinostat Mesylate 15.0mg/m2
Description: Purinostat Mesylate 15.0mg/m2 + EM 25mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B group Purinostat Mesylate 6.0mg/m2
Description: Purinostat Mesylate 6.0mg/m2 + Tislelizumab 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B group Purinostat Mesylate 8.4 mg/m2
Description: Purinostat Mesylate 8.4mg/m2 + Tislelizumab 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B group Purinostat Mesylate 11.2 mg/m2
Description: Purinostat Mesylate 11.2mg/m2 + Tislelizumab 200mg
Study: NCT05868772

Intervention type: DEVICE
Intervention: Active Sentry Handpiece
Description: With low IOP settings

Intervention type: DEVICE
Intervention: Ozil Handpiece
Description: With high IOP settings.
Study: NCT04750850

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic core stability exercises
Description: exercises focused on trunk muscle strengthening, proprioception, selective movements of the trunk and pelvis muscle, and coordination, and will be carried out in supine, sitting on a stable surface and sitting on an unstable surface (ball). The exercise involves changes in the position of the body with or without resistance, aiming to improve strength, endurance, proprioception and coordination. Training is determined by the patient's ability to undertake easy exercises and progress to more challenging exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual routine as walking and activities of daily living.
Study: NCT06431243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B group Purinostat Mesylate 15.0 mg/m2
Description: Purinostat Mesylate 15.0mg/m2 + Tislelizumab 200mg
Study: NCT04960644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: MTX (5-10 mg/day,Dmax 10mg/day) was given on days 1, 3, and 8, and repeated weekly until aGVHD was CR

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: corticosteroid Methylprednisolone 1 mg/kg/day was given for 10 days and then the dosage was gradually reduced according to patient's response
Study: NCT00240851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetaminophen extended release
Study: NCT04995172

Intervention type: PROCEDURE
Intervention: Computed Tomography
Description: Undergo mobile CT-assisted bronchoscopy

Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Patients' medical records are reviewed

Intervention type: PROCEDURE
Intervention: Endobronchial Ultrasound Bronchoscopy
Description: Undergo radial probe EBUS
Study: NCT00859001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FM+R
Description: Fludarabine-Mitoxantrone-Rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zevalin (Ibritumomab Tiuxetan)
Study: NCT05357326

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine Sulfate 0.01% Eye Drop
Description: use one drop into subconjunctiva

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthokeratology
Description: wear orthokeratology at night while sleeping

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine Sulfate 0.04% Eye Drop
Description: use one drop into subconjunctiva
Study: NCT04848454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab with vinorelbine and cisplatin
Description: Camrelizumab: 200mg iv., every 3 weeks(one cycle), for 1 year(17cycles in total); Vinorelbine: 25mg/m2 day 1, 8 iv. or 60-80 mg/m2 or. day1, 8, every 3 weeks(one cycle), for 6 cycles; Cisplatin: 75mg/m2 (divided into 2 days), every 3 weeks(onr cycle), for 6 cycles.
Study: NCT05160558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB132
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB132
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB132
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB132
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB132
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB132-Matching Placebo
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB132-Matching Placebo
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB132-Matching Placebo
Description: Administered as specified in the treatment arm
Study: NCT05598814

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mepolizumab Injection
Description: All patients in both the intervention group and the control group will be treated with Mepolizumab injections every month.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mepolizumab Injection
Description: All patients in both the intervention group and the control group will be treated with Mepolizumab injections every month.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Functional Endoscopic Sinus Surgery (FESS).
Description: The Functional Endoscopic Sinus Surgery will be performed 2 weeks after the first injection of Mepolizumab in the intervention group.
Study: NCT04885101

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LISWT Group
Description: The treatment consists of a weekly session and 4,000 pulses will be emitted each of the eight sessions totaling 32,000 pulses with a frequency of 18Hz and 100mJ of energy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NARFT Group
Description: The device used will be with an intensity of 350 Wpp; 75% pulsed operation mode; frequency of 640 kHz, 1200 kHz and 2400 kHz. Eight radio frequency sessions will be held with an interval of seven days between them.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Group
Description: In the RNA group, radiofrequency will be applied, the device used will be the Nèartek Esthetic Ibramed - Tecarterapia e Radiofrequency Apparatus, with an intensity of 350 Wpp; 75% pulsed operation mode; frequency of 640 kHz, 1200 kHz and 2400 kHz. The radiofrequency will be applied with the patient in the supine position on both sides of the penis with an opposite dispersion plate against the radiofrequency emitter. To perform the procedure, the therapist will use a glove. Eight radio frequency sessions will be held with an interval of seven days between them.
Study: NCT06310382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GH55
Description: GH55 capsule is a novel small molecule, highly selective dual-mechanism ERK1/2 inhibitor developed by Suzhou Genhouse Bio. Co., Ltd. This product can be used to treat cancers caused by abnormal activation of the MAPK pathway (mutational activation of RAS/RAF/MEK) by targeted inhibition of ERK1/2.
Study: NCT06233578

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RADPAD
Description: The RADPAD protection drape was designed as a protective scatter-radiation absorbing shield with the goal of reducing scatter radiation. It is a sterile, lead free, light weight, and disposable radiation protection shield that is placed directly over the sterile patient drapes. The RADPAD is comprised of antimony and bismuth providing protection during low-energy fluoroscopy and high-energy cine and Digital subtraction angiography (DSA) settings.
Study: NCT05811702

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A randomized acute controlled trial of twenty-eight healthy overweight or obese women
Description: A randomized acute controlled trial of twenty-eight healthy overweight or obese women in Saudi Arabia, aged between 18 and 40 with a body mass index between 25 and 34.5 kg m2 and fat parentage above 30% . The participants have followed ether HFKD or LFD for 12 weeks. Our primary outcome of this study to investigated the effective diets HFKD and LFD on reduction of body weight, the percentage of body fat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A randomized acute controlled trial of twenty-eight healthy overweight or obese women
Description: A randomized acute controlled trial of twenty-eight healthy overweight or obese women in Saudi Arabia, aged between 18 and 40 with a body mass index between 25 and 34.5 kg m2 and fat parentage above 30% . The participants have followed ether HFKD or LFD for 12 weeks. Our primary outcome of this study to investigated the effective diets HFKD and LFD on reduction of body weight, the percentage of body fat
Study: NCT05160558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB132-Matching Placebo
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB132-Matching Placebo
Description: Administered as specified in the treatment arm
Study: NCT05936034

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patients suffering from chemotherapy-induced ototoxicity
Description: At baseline,~* medical staff carries out a clinical and audiometric and/or tintometric examination~* patient completes the SF36 survey (36 Item Short-Form Health Survey)~* Patients will then be randomized to either:~  * Control group: standard support; Once the patient has been fit, he continues his carcinological treatment with platinum-based chemotherapy according to the recommendations specific to his pathology.~At one, three and six months after fitting,~* medical staff carries out a clinical examination~* This visit will be scheduled when the patient arrives as part of their standard care. all patients included in the study will have a clinical examination and an audiometric and/or tinnitus examination and should complete an SF36 quality of life questionnaire.~Only at the last visit (6 months) all patients included should complete a satisfaction questionnaire.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patients suffring from chemotherapy-induced ototoxicity wearing hearing aids
Description: At baseline,~* medical staff carries out a clinical and audiometric and/or tintometric examination~* patient completes the SF36 survey (36 Item Short-Form Health Survey)~* Patients will then be randomized to either:~  * Experimental group: standard treatment with hearing aids (wearing a hearing aid).~Once the patient has been fit, he continues his carcinological treatment with platinum-based chemotherapy according to the recommendations specific to his pathology.~At one, three and six months after fitting,~* medical staff carries out a clinical examination~* This visit will be scheduled when the patient arrives as part of their standard care. all patients included in the study will have a clinical examination and an audiometric and/or tinnitus examination and should complete an SF36 quality of life questionnaire.~Only at the last visit (6 months) all patients included should complete a satisfaction questionnaire.
Study: NCT05196360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAX-10181
Description: Part 1: Dose escalation, MAX-10181 once or twice daily with dose modifications based on tolerability criteria.~Part 2: Dose expansion, Recommended doses from Part 1.
Study: NCT05518266

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: US-guided Parasternal block
Description: Bupivacaine 0.25 % will be injected into the fascial plane between the pectoralis major muscle and external intercostal muscle or costal cartilages on each side of sternum after skin closure under ultrasound guidance

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgeon-delivered parasternal block
Description: Just before wiring of the sternum, the surgeon will inject bupivacaine 0.25 % in 4 mL aliquots into the anterior (2nd-6th) intercostal spaces on each side about 2 cm lateral to the sternal edge with a total volume of 40 mL under direct vision.
Study: NCT06415266

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of life questionnaire (QLQ)
Description: Quality of life questionnaire : EORTC QLQ-C30, EORTC QLQ-Breast cancer module (BR) 23, EORTC SHQ-C22 et HADS at inclusion, visit 1 (6 months +/-1 month before the inclusion), visit 2 (12 months +/-1 month before the inclusion), visit 3 (18 months +/-1 month before the inclusion) and visit 4 (24 months +/-1 month before the inclusion).

Intervention type: OTHER
Group type: OTHER
Intervention: Quality of life questionnaire (QLQ)
Description: Quality of life questionnaire : EORTC QLQ-C30, EORTC QLQ-Breast cancer module (BR) 23, EORTC SHQ-C22 et HADS at inclusion, visit 1 (6 months +/-1 month before the inclusion), visit 2 (12 months +/-1 month before the inclusion), visit 3 (18 months +/-1 month before the inclusion) and visit 4 (24 months +/-1 month before the inclusion).
Study: NCT05380687

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Inspiratory hold
Description: A short period (\< 30 seconds) during which both inspiratory and expiratory valves of the ventilator circuit are closed at the end of inspiration. It is used to asses expiratory force generation (maximal expiratory pressure, MEP) and frequently used in clinical practice.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Inspiratory hold
Description: A short period (\< 30 seconds) during which both inspiratory and expiratory valves of the ventilator circuit are closed at the end of inspiration. It is used to asses expiratory force generation (maximal expiratory pressure, MEP) and frequently used in clinical practice.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Expiratory hold
Description: A short period (\< 30 seconds) during which both inspiratory and expiratory valves of the ventilator circuit are closed at the end of expiration. It is used to asses static PEEP and inspiratory force generation (maximal inspiratory pressure, MIP \& occlusion pressure, ∆Pocc) and is frequently used in clinical practice.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Expiratory hold
Description: A short period (\< 30 seconds) during which both inspiratory and expiratory valves of the ventilator circuit are closed at the end of expiration. It is used to asses static PEEP and inspiratory force generation (maximal inspiratory pressure, MIP \& occlusion pressure, ∆Pocc) and is frequently used in clinical practice.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound of respiratory muscles
Description: Ultrasound of the diaphragm, parasternal intercostal muscle and internal oblique muscle will be performed during each block. Thickening fractions, calculated as thickness at end-inspiration minus thickness at end-expiration divided by thickness at end-expiration, are used to assess the contribution of the muscle to the tidal volume. A median over 5 breaths will be calculated.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound of respiratory muscles
Description: Ultrasound of the diaphragm, parasternal intercostal muscle and internal oblique muscle will be performed during each block. Thickening fractions, calculated as thickness at end-inspiration minus thickness at end-expiration divided by thickness at end-expiration, are used to assess the contribution of the muscle to the tidal volume. A median over 5 breaths will be calculated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEP 10
Description: Positive End-Expiratory Pressure of 10cmH2O for 30 minutes
Study: NCT06415266

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Satisfaction survey
Description: The satisfaction score will be collected using a visual analog scale from 0 to 10 and the satisfaction questionnaire will also be completed at visit 4 (24 months +/- 1 month before the inclusion).

Intervention type: OTHER
Group type: OTHER
Intervention: Satisfaction survey
Description: The satisfaction score will be collected using a visual analog scale from 0 to 10 and the satisfaction questionnaire will also be completed at visit 4 (24 months +/- 1 month before the inclusion).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment of patient needs in the field of oncosexology
Description: Assessment of patient needs in the field of oncosexology during a face-to-face or virtual interview at inclusion and every 6 months for 2 years. If a need is identified, an oncosexology consultation will be organised. Following this, a personalised care plan may be proposed.
Study: NCT05695092

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation
Description: Progressive Muscle Relaxation (PMR): This method involved efficiently relaxing global muscles of body with the objective of mental and physical relaxation.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: control
Description: control group will not receive any intervention
Study: NCT05707143

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: home based stabilization exercises
Description: 3 times per day with 10 repetitions and holding time will be 5-10 sec
Study: NCT04816487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium Iodide or Glutathione
Description: Patient will receive either Glutathione or Potassium iodide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium Iodide or Glutathione
Description: Patient will receive either Glutathione or Potassium iodide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium Iodide or Glutathione
Description: Patient will receive either Glutathione or Potassium iodide
Study: NCT06131892

Intervention type: OTHER
Intervention: Defibrillation
Description: Defibrillation

Intervention type: OTHER
Intervention: Defibrillation
Description: Defibrillation

Intervention type: OTHER
Intervention: Defibrillation
Description: Defibrillation

Intervention type: OTHER
Intervention: Defibrillation
Description: Defibrillation
Study: NCT06111040

Intervention type: OTHER
Group type: OTHER
Intervention: Measurement
Description: The only interventions are at the measurement level and consist of two behavioral protocols designed to assess children's eating behavior, where food stimuli are provided and children's behavioral responses are recorded.
Study: NCT05861063

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser
Description: All patients were given oral administration of 0.5mg paronosetron hydrochloride and lidocaine cream 1 hour before surgery. After cleaning and disinfection, fractional CO2 laser treatment was given. Among them, the fractional CO2 laser laser (American Medical Laser company) selected relatively constant energy parameters in the treatment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser
Description: All patients were given oral administration of 0.5mg paronosetron hydrochloride and lidocaine cream 1 hour before surgery. After cleaning and disinfection, fractional CO2 laser treatment was given. Among them, the fractional CO2 laser laser (American Medical Laser company) selected relatively constant energy parameters in the treatment

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Fractional CO2 laser
Description: All patients were given oral administration of 0.5mg paronosetron hydrochloride and lidocaine cream 1 hour before surgery. After cleaning and disinfection, fractional CO2 laser treatment was given. Among them, the fractional CO2 laser laser (American Medical Laser company) selected relatively constant energy parameters in the treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dezocine
Description: Desocine injection was injected intravenously half an hour before surgery (10ml normal saline was added for more than 30 seconds)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dezocine
Description: Desocine injection was injected intravenously half an hour before surgery (10ml normal saline was added for more than 30 seconds)
Study: NCT04959136

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambulatory Monitoring Solution
Description: Aim is to evaluate PR; RR; NIBP, cNIBP, SpO2 and arterial blood pressure with investigational Ambulatory Monitoring Solution (AMS)
Study: NCT06436144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Etoposide Soft Capsules Dosage：25mg/tablet, 2 tablets/time, taken continuously for 21 days, and stopped for one week. Osimertinib Dosage：80mg/tablet, 1 tablet/time, QD, taken for two cycles.
Study: NCT05707143

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kegel exercises
Description: 3 times per day with 10 repetitions and holding time will be 5-10 sec
Study: NCT06048406

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Health education
Description: The intervention group will receive a health education intervention focused on influenza vaccination literacy, while the control group will continue with their standard school health education without any additional intervention. An influenza vaccination health education including topics such as the importance of influenza vaccination, benefits of vaccination, and vaccination methods, will be developed and reviewed by an expert group. The package for the intervention group will include educational activities, distribution of promotional materials, vaccination services, and distribution of vaccination souvenirs.
Study: NCT05380687

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEP 10
Description: Positive End-Expiratory Pressure of 10cmH2O for 30 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEP 5
Description: Positive End-Expiratory Pressure of 5cmH2O for 30 minutes
Study: NCT05602610

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05380687

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEP 5
Description: Positive End-Expiratory Pressure of 5cmH2O for 30 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEP 0
Description: Positive End-Expiratory Pressure of 0cmH2O for 30 minutes
Study: NCT05366270

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WBH
Description: Hyperthermia exposure using Heckel Hyperthermia Device

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham (mild heating) using Heckel Hyperthermia Device
Study: NCT06021678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EX103 injection
Description: Administered as specified in the treatment arm.